Abstract
Sepsis is one of the major health problems all over the word. Its pathophysiological mechanisms are not completely understood, but coagulation alterations are a hallmark of this syndrome. There is a clear exacerbation of coagulation and a suppression of control mechanisms of this process, including a reduction in fibrinolysis with consequent impairment of fibrin removal. The leading cause of these alterations is the proinflammatory state of those patients, characterized by high cytokine levels, increase in adhesion molecules expression, endothelial and platelets activation, release of microparticles and other related phenomena. Moreover, coagulation and inflammation are linked in a variety of pathways with mutual activation that ultimately contributes for its maintenance. The components of this process will be herein discussed as well as therapeutical alternatives that have excessive coagulation as a target.
Keywords: Antithrombin, disseminated intravascular coagulation, inflammation mediators, protein c, sepsis, tissue factor pathway inhibitor
Endocrine, Metabolic & Immune Disorders - Drug Targets
Title: Sepsis, Coagulation and Anticoagulants
Volume: 10 Issue: 3
Author(s): Flavia Ribeiro Machado and Murillo Santucci Cesar
Affiliation:
Keywords: Antithrombin, disseminated intravascular coagulation, inflammation mediators, protein c, sepsis, tissue factor pathway inhibitor
Abstract: Sepsis is one of the major health problems all over the word. Its pathophysiological mechanisms are not completely understood, but coagulation alterations are a hallmark of this syndrome. There is a clear exacerbation of coagulation and a suppression of control mechanisms of this process, including a reduction in fibrinolysis with consequent impairment of fibrin removal. The leading cause of these alterations is the proinflammatory state of those patients, characterized by high cytokine levels, increase in adhesion molecules expression, endothelial and platelets activation, release of microparticles and other related phenomena. Moreover, coagulation and inflammation are linked in a variety of pathways with mutual activation that ultimately contributes for its maintenance. The components of this process will be herein discussed as well as therapeutical alternatives that have excessive coagulation as a target.
Export Options
About this article
Cite this article as:
Ribeiro Machado Flavia and Santucci Cesar Murillo, Sepsis, Coagulation and Anticoagulants, Endocrine, Metabolic & Immune Disorders - Drug Targets 2010; 10 (3) . https://dx.doi.org/10.2174/187153010791936892
DOI https://dx.doi.org/10.2174/187153010791936892 |
Print ISSN 1871-5303 |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-3873 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Coronary CT and the Coronary Calcium Score, the Future of ED Risk Stratification?
Current Cardiology Reviews Genetics of Polygenic Hypertension from Animal Models to Humans
Current Hypertension Reviews Effect of Depression on Self-Management Behaviors and Health Outcomes in Adults with Type 2 Diabetes
Current Diabetes Reviews The Current Status and Future Perspectives of Studies of Cannabinoid Receptor 1 Antagonists as Anti-Obesity Agents
Current Topics in Medicinal Chemistry The Evolution of Pharmacological Treatment for Parkinsons Disease
Recent Patents on CNS Drug Discovery (Discontinued) Modification of Decoy Oligodeoxynucleotides to Achieve the Stability and Therapeutic Efficacy
Current Topics in Medicinal Chemistry Radiolabeled Probes Targeting Tyrosine-Kinase Receptors For Personalized Medicine
Current Pharmaceutical Design Affinity Ligands for Industrial Protein Purification
Protein & Peptide Letters Garlic for Cardiovascular Disease: Prevention or Treatment?
Current Pharmaceutical Design Current Status of Leukemia Cytotherapy - Exploitation with Immune Cells
Current Stem Cell Research & Therapy Mitochondrial Dysfunction and Antioxidant Therapy in Sepsis
Infectious Disorders - Drug Targets MDR1/P-Glycoprotein (ABCB1) as Target for RNA Interference-Mediated Reversal of Multidrug Resistance
Current Drug Targets Dietary Fatty Acids in Metabolic Syndrome, Diabetes and Cardiovascular Diseases
Current Diabetes Reviews The Influence of Genetic Variations and Drug Interactions Based on Metabolism of Antidepressants and Anticonvulsants
Current Drug Metabolism The Secretin/Pituitary Adenylate Cyclase-Activating Polypeptide/ Vasoactive Intestinal Polypeptide Superfamily in the Central Nervous System
Central Nervous System Agents in Medicinal Chemistry Pharmacogenetically Tailored Treatments for Heart Disease
Current Pharmaceutical Design Difference in Blood Pressure Measurements Between Arms: Methodological and Clinical Implications
Current Pharmaceutical Design The Promises and Challenges of the Use of Genomics in the Prescription of Exercise for Hypertension: The 2013 Update
Current Hypertension Reviews GnRH-Agonist Triggering to Avoid Ovarian Hyperstimulation Syndrome: A Review of the Evidence
Current Drug Targets TRYCAT Pathways Link Peripheral Inflammation, Nicotine, Somatization and Depression in the Etiology and Course of Parkinson’s Disease
CNS & Neurological Disorders - Drug Targets